Glycostem welcomes Dr Rizwan Romee as US based advisor

September 2019: Glycostem announced that associate professor Rizwan Romee of Harvard Medical School/Dana Faber Cancer Institute will be joining its Advisory Board.

Please click here to open.

Glycostem signs first 1st commercial agreement for oNKord® and new CAR-NK co-development agreement

September 2019: Glycostem announced that it has entered into a sales and marketing agreement for oNKord® in Korea and Japan for the indications of AML and MM. Furthermore a global CAR-NK co-development agreement has been signed

Please click here to open.

Glycostem successfully completes funding round

September 2019: Glycostem announces that it has successfully raised funding for important clinical trials and corporate investments from Korean and Dutch investors.

Please click here to open.

Glycostem raises €5 million for clinical trials

September 2019: Glycostem announces that it has secured a €5 million loan to cover some of the clinical trial activities the company will engage in early 2020.

Please click here to open file.

Glycostem received GMP license for oNKord®

June 2019: Glycostem proudly announce receiving GMP license.

Please click here to open the file.

Glycostem appoints Chief Medical Officer

June 2019: Glycostem Therapeutics BV announces Didier Haguenauer, MD as Glycostem’s new Chief Medical Officer.

Please click here here to open file.

Glycostem and Phio team up

March 2019: Glycostem and Phio team up to identify new and more effective ways for expanding and differentiating NK-cells using Phio’s sd-rxRNA® platform

Please click here to open file.

Glycostem partners with Marie Curie

December 2018: Glycostem is proud to be commercial partner in the Marie Curie “Mature-NK” programme. The funding for the CAR-NK technology will be well invested.

Please click here to open file.

Glycostem technology is awarded research grant

December 2018: Together with Enpicom Glycostem has been awarded funding to develop cancer prediction tool for an area without standard therapy.

Please click here to open file.

MolMed and Glycostem Cooperation

June 2018: MolMed and Glycostem announce the execution of a binding term sheet for the development and manufacturing of allogeneic CAR-NK therapies.

Please click here to open file.

Eurostars Granted Project

May 2018: Eurostars Granted Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK

Please click here to open file.

Glycostem Clinical Data Recap

January 2018: Peer reviewed phase 1 trial

Please click here to open file.

Lupus Ventures takes stake in Glycostem

December 2017: Momentum continues to build in advance of Glycostem’s pivotal 2019 trials.

Please click here to open file.

Management momentum in advance of pivotal trial

November 2017: Glycostem expands management team in expansion phase.

Please click here to open file.

Glycostem listed in independent article

November 2016;

Glycostem is delighted that we have been listed as the only not-public listed company in this article. If you are interested in the NK cell space, this is a recommended read.

Read more >

Orphan-Drug Designation request of NK Cell Product oNKord® granted by FDA

April 20, 2016
On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKord® for treatment of acute myeloid leukemia (AML)

Glycostem launches its new website

On the 2nd December Glycostem has officially launched its new website, which provides a comprehensive overview of our current position and ambitious plans on the application of NK cell immunotherapy in the treatment of cancer.

Read more >

Glycostem's NK Cell Product oNKord® received Orphan drug designation for AML

ODD for NK Cell Product oNKord® to treat AML

Read more >

Glycostem settles its R&D department at Pivot Park in Oss

New home for Glycostem's R&D

Read more >

Subscribe to our newsletter

If you subscribe you agree to the Privacy Notice of Glycostem Therapeutics B.V. as found on the website.